Meta-analysis of surrogate endpoints for overall survival in extensive-stage small-cell lung cancer
PFS demonstrates strong clinical value as a surrogate endpoint for OS in the first-line SCLC setting, including with chemoimmunotherapy, and may serve as a reliable endpoint for future phase III trials. In contrast, ORR and DCR do not reliably predict long-term outcomes, underscoring the need to prioritize PFS over these measures in trial design and interpretation.
Authors
- Afshin Dowlati (ORCID: https://orcid.org/0000-0003-4535-6839)
- Pingfu Fu (ORCID: https://orcid.org/0000-0002-2334-5218)
- Seren Durer (ORCID: https://orcid.org/0009-0008-5105-4689)
- Zhengyi Chen (ORCID: https://orcid.org/0000-0002-2745-4454)
Institutions
- University Hospitals Seidman Cancer Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105843
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00